MimiVax
2012
FOUNDED
PRIVATE
STATUS
Later Stage VC
LATEST DEAL TYPE
(Cancelled)
$10M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of immunotherapeutic vaccines and targeted therapies designed to control tumor growth and recurrence. The company's vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to cure their patients.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Elm & Carlton Streets
- Buffalo-Niagara Downtown, Medical Corridor
- Buffalo, NY 14263
- United States
+1 (716) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore MimiVax’s full profile, request a free trial.
MimiVax Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 02-Aug-2019 | $10M | Cancelled | Clinical Trials - Phase 2 | ||
| 4. Early Stage VC | 000 | 000 | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series A) | 25-Aug-2015 | 00.000 | 000 | Completed | Startup | |
| 2. Grant | 01-Mar-2015 | $2M | $450K | Completed | Startup | |
| 1. Seed Round | 01-Jan-2012 | $450K | $450K | Completed | Startup |
MimiVax Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Buffalo Capital Partners | Impact Investing | Minority | 000 0000 | 000000 0 | ||
| Roswell Park Cancer Institute | Corporation | Minority | 000 0000 | 000000 0 |